Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Current Treatment Options in Oncology

• Publication date

  2023-11-14

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1007/s11864-023-01143-7PMID 37962824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gingival mesenchymal stem cell therapy, immune cells, and immunoinflammatory application

  2023cited by this paper
• Cytokine sustained delivery for cancer therapy; special focus on stem cell- and biomaterial- based delivery methods.

  2023cited by this paper
• Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities

  2023cited by this paper
• Cancer vaccines as promising immuno-therapeutics: platforms and current progress

  2022cited by this paper
• CTLA-4; as an immunosuppressive immune checkpoint in breast cancer.

  2022cited by this paper
• Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies

  2022cited by this paper
• Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.

  2022cited by this paper
• Adverse Events and Side Effects of Chimeric Antigen Receptor (CAR) T Cell Therapy in Patients with Hematologic Malignancies

  2021cited by this paper
• Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers

  2021cited by this paper
• Harnessing dendritic cells for innovative therapeutic cancer vaccines

  2021cited by this paper
• Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

  2021cited by this paper
• Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities

  2021cited by this paper
• Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method

  2021cited by this paper
• Therapeutic cancer vaccines

  2021cited by this paper
• Genetic models of human and mouse dendritic cell development and function

  2020cited by this paper
• Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites

  2020cited by this paper
• Whole leukemia cell vaccines: Past progress and future directions.

  2020cited by this paper
• Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy

  2020cited by this paper
• Ex vivo pulsed dendritic cell vaccination against cancer

  2020cited by this paper
• Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses

  2020cited by this paper
• Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma

  2020cited by this paper
• Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia

  2020cited by this paper
• DC-Based Vaccines for Cancer Immunotherapy

  2020cited by this paper
• Antitumour dendritic cell vaccination in a priming and boosting approach

  2020cited by this paper
• Can Dendritic Cell Vaccination Prevent Leukemia Relapse?

  2019cited by this paper
• Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine

  2019cited by this paper
• Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

  2019cited by this paper
• Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity

  2019cited by this paper
• Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

  2019cited by this paper
• Dendritic cells in cancer immunology and immunotherapy

  2019cited by this paper
• The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

  2019cited by this paper
• Dendritic cell subsets in T cell programming: location dictates function

  2018cited by this paper
• Human dendritic cell subsets: an update

  2018cited by this paper
• Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

  2018cited by this paper
• Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

  2018cited by this paper
• BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

  2018cited by this paper
• Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells

  2017cited by this paper
• Revisiting GM-CSF as an adjuvant for therapeutic vaccines

  2017cited by this paper
• Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

  2017cited by this paper
• Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

  2017cited by this paper
• Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

  2017cited by this paper
• Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation

  2017cited by this paper
• Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.

  2017cited by this paper
• Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors

  2017cited by this paper
• Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity

  2016cited by this paper
• Dendritic cell-based immunotherapy

  2016cited by this paper
• The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies

  2016cited by this paper
• Dendritic cell-based vaccine for pancreatic cancer in Japan.

  2016cited by this paper
• Dendritic cell-based vaccine research against cancer

  2015cited by this paper
• Circulating precursors of human CD1c+ and CD141+ dendritic cells

  2015cited by this paper
• Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

  2015cited by this paper
• Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

  2015cited by this paper
• Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas

  2014cited by this paper
• Dendritic cell vaccine against leukemia: advances and perspectives.

  2014cited by this paper
• Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

  2013cited by this paper
• IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

  2013cited by this paper
• Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients

  2013cited by this paper
• Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

  2013cited by this paper
• Identification of human tissue cross-presenting dendritic cells

  2013influential reference
• Ontogeny and functional specialization of dendritic cells in human and mouse.

  2013cited by this paper
• Novel perspectives on dendritic cell-based immunotherapy of cancer.

  2013cited by this paper
• Critical Roles of a Dendritic Cell Subset Expressing a Chemokine Receptor, XCR1

  2013cited by this paper
• Decisions about dendritic cells: past, present, and future.

  2012cited by this paper
• Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma

  2012cited by this paper
• Cancer immunotherapy via dendritic cells

  2012cited by this paper
• HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.

  2012cited by this paper
• Deciphering the message broadcast by tumor-infiltrating dendritic cells.

  2012cited by this paper
• Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

  2012cited by this paper
• PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

  2011cited by this paper
• Autoimmunity associated with immunotherapy of cancer.

  2011cited by this paper
• Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis

  2011cited by this paper
• Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens

  2010cited by this paper
• Designing vaccines based on biology of human dendritic cell subsets.

  2010cited by this paper
• Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells

  2010cited by this paper
• Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

  2010cited by this paper
• Suppressive Influences in the Immune Response to Cancer

  2009cited by this paper
• Dendritic cells dysfunction in tumour environment.

  2008cited by this paper
• Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma

  2007cited by this paper
• Dendritic cell vaccines for leukemia patients

  2007cited by this paper
• Taking dendritic cells into medicine

  2007cited by this paper
• Phase I/II study of vaccination with dendritic‐like leukaemia cells for the immunotherapy of acute myeloid leukaemia

  2006cited by this paper
• Cancer immunotherapy using dendritic/tumour‐fusion vaccine induces elevation of serum anti‐nuclear antibody with better clinical responses

  2006cited by this paper
• Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.

  2005cited by this paper
• Clinical applications of dendritic cell vaccination in the treatment of cancer

  2004cited by this paper
• Inhibition of Phosphatidylserine Recognition Heightens the Immunogenicity of Irradiated Lymphoma Cells In Vivo

  2004cited by this paper
• Hybrid Cell Vaccination in Metastatic Melanoma: Clinical and Immunologic Results of a Phase I/II Study

  2004cited by this paper
• Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12

  2004cited by this paper
• Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen.

  2003cited by this paper
• The Treatment of Patients With Disseminated Malignant Melanoma by Vaccination With Autologous Cell Hybrids of Tumor Cells and Dendritic Cells

  2002cited by this paper
• Antigen presentation and T cell stimulation by dendritic cells.

  2002cited by this paper
• Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells

  2001cited by this paper
• Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model

  2001cited by this paper
• Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

  2001cited by this paper
• The allogeneic response and tumor immunity

  2001cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1

  2001cited by this paper
• Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma

  2000cited by this paper
• A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

  1999cited by this paper
• Migration of cultured chimpanzee dendritic cells following intravenous and subcutaneous injection.

  1997cited by this paper

• Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer

  2026cites this paper
• Immunological Effects of Proton Radiotherapy: New Opportunities and Challenges in Cancer Therapy

  2025cites this paper
• SLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis

  2025influential citation
• Hydrogel-Based Vaccines: A Promising Approach for Cancer Immunotherapy

  2025cites this paper
• Immune cell-based therapies for solid tumors, current challenges and therapeutic advances

  2025cites this paper
• Trial watch: anticancer vaccination with dendritic cells

  2024cites this paper